Mitochondrial RNA methyltransferase TRMT61B is a new, potential biomarker and therapeutic target for highly aneuploid cancers.


Journal

Cell death and differentiation
ISSN: 1476-5403
Titre abrégé: Cell Death Differ
Pays: England
ID NLM: 9437445

Informations de publication

Date de publication:
01 2023
Historique:
received: 23 05 2021
accepted: 09 07 2022
revised: 27 06 2022
pmc-release: 01 01 2024
pubmed: 23 7 2022
medline: 1 2 2023
entrez: 22 7 2022
Statut: ppublish

Résumé

Despite being frequently observed in cancer cells, chromosomal instability (CIN) and its immediate consequence, aneuploidy, trigger adverse effects on cellular homeostasis that need to be overcome by anti-stress mechanisms. As such, these safeguard responses represent a tumor-specific Achilles heel, since CIN and aneuploidy are rarely observed in normal cells. Recent data have revealed that epitranscriptomic marks catalyzed by RNA-modifying enzymes change under various stress insults. However, whether aneuploidy is associated with such RNA modifying pathways remains to be determined. Through an in silico search for aneuploidy biomarkers in cancer cells, we found TRMT61B, a mitochondrial RNA methyltransferase enzyme, to be associated with high levels of aneuploidy. Accordingly, TRMT61B protein levels are increased in tumor cell lines with an imbalanced karyotype as well as in different tumor types when compared to control tissues. Interestingly, while TRMT61B depletion induces senescence in melanoma cell lines with low levels of aneuploidy, it leads to apoptosis in cells with high levels. The therapeutic potential of these results was further validated by targeting TRMT61B in transwell and xenografts assays. We show that TRM61B depletion reduces the expression of several mitochondrial encoded proteins and limits mitochondrial function. Taken together, these results identify a new biomarker of aneuploidy in cancer cells that could potentially be used to selectively target highly aneuploid tumors.

Identifiants

pubmed: 35869285
doi: 10.1038/s41418-022-01044-6
pii: 10.1038/s41418-022-01044-6
pmc: PMC9883398
doi:

Substances chimiques

RNA, Mitochondrial 0
Methyltransferases EC 2.1.1.-
RNA 63231-63-0
Biomarkers 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

37-53

Informations de copyright

© 2022. The Author(s), under exclusive licence to ADMC Associazione Differenziamento e Morte Cellulare.

Références

Mol Cancer Ther. 2010 May;9(5):1080-91
pubmed: 20442302
Nat Rev Mol Cell Biol. 2015 Aug;16(8):473-85
pubmed: 26204159
Nat Commun. 2020 Jan 30;11(1):588
pubmed: 32001709
PLoS Biol. 2016 Sep 15;14(9):e1002557
pubmed: 27631568
Nat Rev Cancer. 2020 Jun;20(6):303-322
pubmed: 32300195
Wiley Interdiscip Rev RNA. 2020 Sep;11(5):e1595
pubmed: 32301288
PLoS Genet. 2011 Apr;7(4):e1002057
pubmed: 21552543
Cancers (Basel). 2019 Feb 15;11(2):
pubmed: 30781398
Annu Rev Genomics Hum Genet. 2014;15:127-50
pubmed: 24898039
Cell. 2011 Feb 18;144(4):499-512
pubmed: 21315436
Mol Cancer. 2021 Jan 18;20(1):18
pubmed: 33461542
J Biol Chem. 2002 May 10;277(19):16391-5
pubmed: 11861649
Cell Metab. 2020 Sep 1;32(3):341-352
pubmed: 32668195
Mol Cancer. 2012 Oct 09;11:76
pubmed: 23043612
Autophagy. 2013 Feb 1;9(2):246-8
pubmed: 23108329
Cancer Cell. 2018 Apr 9;33(4):676-689.e3
pubmed: 29622463
Oncotarget. 2016 Sep 27;7(39):63913-63923
pubmed: 27590505
J Gastrointest Oncol. 2021 Aug;12(4):1384-1397
pubmed: 34532096
RNA Biol. 2017 Sep 2;14(9):1138-1152
pubmed: 27911188
Oncogene. 2015 Jul 30;34(31):4044-55
pubmed: 25347746
Cell Cycle. 2015;14(17):2810-20
pubmed: 26151317
Open Biol. 2020 Sep;10(9):200148
pubmed: 32873156
Nat Rev Genet. 2012 Jan 24;13(3):189-203
pubmed: 22269907
Nat Genet. 2003 Aug;34(4):369-76
pubmed: 12923544
Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11283-8
pubmed: 11553793
Nucleic Acids Res. 2006 Feb 01;34(2):721-33
pubmed: 16452298
Cell Cycle. 2011 Dec 1;10(23):4032-8
pubmed: 22101267
Nature. 2018 Jan 25;553(7689):467-472
pubmed: 29342134
Cancer Res. 2018 Dec 15;78(24):6807-6817
pubmed: 30355619
Proc Natl Acad Sci U S A. 2009 May 26;106(21):8671-6
pubmed: 19458043
Nucleic Acids Res. 2018 Jan 4;46(D1):D303-D307
pubmed: 29106616
Nature. 2021 Feb;590(7846):486-491
pubmed: 33505028
Neoplasia. 2017 Aug;19(8):649-658
pubmed: 28732212
EMBO J. 2014 Oct 16;33(20):2374-87
pubmed: 25205676
Biochim Biophys Acta. 1999 Feb 9;1410(2):103-23
pubmed: 10076021
Autophagy. 2016;12(1):1-222
pubmed: 26799652
Nat Rev Mol Cell Biol. 2017 Jan;18(1):31-42
pubmed: 27808276
Mol Syst Biol. 2012;8:608
pubmed: 22968442
BMC Biotechnol. 2017 Feb 28;17(1):24
pubmed: 28245848
Biochim Biophys Acta. 2007 Dec;1773(12):1701-20
pubmed: 18240421
Elife. 2014 Jul 29;3:e03023
pubmed: 25073701
Cancer Res. 2019 Jul 1;79(13):3514-3524
pubmed: 31113817
Bioessays. 2012 Oct;34(10):893-900
pubmed: 22926916
Cancer Res. 2003 Dec 15;63(24):8634-47
pubmed: 14695175
Dev Cell. 2021 Sep 13;56(17):2427-2439.e4
pubmed: 34352222
Dev Cell. 2016 Feb 8;36(3):290-302
pubmed: 26859353
Biochim Biophys Acta. 2012 May;1820(5):595-600
pubmed: 21846491
Int J Mol Sci. 2019 Sep 18;20(18):
pubmed: 31540349
Nat Commun. 2016 Apr 27;7:11375
pubmed: 27117709
Nat Rev Cancer. 2006 Oct;6(10):813-23
pubmed: 16990858
RNA Biol. 2015;12(6):603-14
pubmed: 25892531
PLoS One. 2012;7(8):e40690
pubmed: 22912665
Acta Neuropathol Commun. 2019 Apr 10;7(1):55
pubmed: 30971321
Curr Biol. 2006 Jul 25;16(14):R551-60
pubmed: 16860735
Mol Cell. 2017 Dec 7;68(5):993-1005.e9
pubmed: 29107537
Dev Cell. 2018 Feb 26;44(4):420-431
pubmed: 29486194
Cancer Metab. 2015 Oct 20;3:11
pubmed: 26500770
Dev Cell. 2021 Sep 13;56(17):2440-2454.e6
pubmed: 34352223
Genes Dev. 2015 Oct 1;29(19):2010-21
pubmed: 26404941
Biomolecules. 2020 Sep 30;10(10):
pubmed: 33007949
Cell. 2015 Feb 12;160(4):771-784
pubmed: 25679766
RNA. 2012 Dec;18(12):2269-76
pubmed: 23097428
BMC Cancer. 2018 Jan 2;18(1):3
pubmed: 29291719
Nat Genet. 2006 Sep;38(9):1043-8
pubmed: 16921376
Cancer Res. 2017 Feb 1;77(3):601-612
pubmed: 27923837
Nature. 2015 Mar 19;519(7543):349-52
pubmed: 25731168
Cancer Res. 2017 Nov 1;77(21):5846-5859
pubmed: 28720577
Cancer Res. 2012 Jul 15;72(14):3499-511
pubmed: 22802077
Cell Rep. 2013 Aug 15;4(3):609-20
pubmed: 23933261
Nat Commun. 2019 Dec 12;10(1):5679
pubmed: 31831737
Science. 2007 Aug 17;317(5840):916-24
pubmed: 17702937
Toxics. 2019 Mar 25;7(1):
pubmed: 30934574
Nat Med. 2018 Jul;24(7):1036-1046
pubmed: 29892070
Cell. 2017 Jun 15;169(7):1187-1200
pubmed: 28622506
Curr Opin Cell Biol. 2006 Dec;18(6):658-67
pubmed: 17046232
Cell Cycle. 2014;13(4):622-31
pubmed: 24335260
Curr Biol. 2010 Mar 23;20(6):R285-95
pubmed: 20334839
Nat Rev Cancer. 2021 Feb;21(2):89-103
pubmed: 33432169
Biomed Res Int. 2014;2014:832704
pubmed: 25013806

Auteurs

Alberto Martín (A)

Gene Therapy Unit, Instituto de Investigación de Enfermedades Raras, Instituto de Salud Carlos III (ISCIII), Madrid, Spain. martin.alberto77@gmail.com.

Carolina Epifano (C)

Gene Therapy Unit, Instituto de Investigación de Enfermedades Raras, Instituto de Salud Carlos III (ISCIII), Madrid, Spain.

Borja Vilaplana-Marti (B)

Gene Therapy Unit, Instituto de Investigación de Enfermedades Raras, Instituto de Salud Carlos III (ISCIII), Madrid, Spain.

Iván Hernández (I)

Gene Therapy Unit, Instituto de Investigación de Enfermedades Raras, Instituto de Salud Carlos III (ISCIII), Madrid, Spain.

Rocío I R Macías (RIR)

Experimental Hepatology and Drug Targeting (HEVEPHARM) Group, University of Salamanca, Biomedical Research Institute of Salamanca (IBSAL), Salamanca, Spain.
National Institute for the Study of Liver and Gastrointestinal Diseases, CIBERehd, Carlos III Health Institute, Madrid, Spain.

Ángel Martínez-Ramírez (Á)

Department of Molecular Cytogenetics, MD Anderson Cancer Center, Madrid, Spain.
Oncohematology Cytogenetics Laboratory, Eurofins-Megalab, Madrid, Spain.

Ana Cerezo (A)

Lilly Cell Signaling and Immunometabolism Section, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.

Pablo Cabezas-Sainz (P)

Department of Zoology, Genetics and Physical Anthropology, Universidade de Santiago de Compostela, Campus de Lugo, 27002, Lugo, Spain.

Maria Garranzo-Asensio (M)

Chronic Disease Program (UFIEC), Instituto de Salud Carlos III (ISCIII), E-28220, Madrid, Spain.

Sandra Amarilla-Quintana (S)

Gene Therapy Unit, Instituto de Investigación de Enfermedades Raras, Instituto de Salud Carlos III (ISCIII), Madrid, Spain.
Programa de Doctorado UNED-ISCIII Ciencias Biomédicas y Salud Pública, Universidad Nacional de Educación a Distancia (UNED), Madrid, Spain.

Déborah Gómez-Domínguez (D)

Gene Therapy Unit, Instituto de Investigación de Enfermedades Raras, Instituto de Salud Carlos III (ISCIII), Madrid, Spain.

Eduardo Caleiras (E)

Histopathology Core Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.

Jordi Camps (J)

Unitat de Recerca Biomèdica, Hospital Universitari de Sant Joan, Institut d'Investigacio´ Sanitària Pere Virgili, Universitat Rovira i Virgili, Reus, Spain.

Gonzalo Gómez-López (G)

Bioinformatics Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.

Marta Gómez de Cedrón (M)

Molecular Oncology Group, Precision Nutrition and Cancer Program, IMDEA FOOD, CEI UAM+CSIC, Madrid, Spain.

Ana Ramírez de Molina (A)

Molecular Oncology Group, Precision Nutrition and Cancer Program, IMDEA FOOD, CEI UAM+CSIC, Madrid, Spain.

Rodrigo Barderas (R)

Chronic Disease Program (UFIEC), Instituto de Salud Carlos III (ISCIII), E-28220, Madrid, Spain.

Laura Sánchez (L)

Department of Zoology, Genetics and Physical Anthropology, Universidade de Santiago de Compostela, Campus de Lugo, 27002, Lugo, Spain.

Susana Velasco-Miguel (S)

Lilly Cell Signaling and Immunometabolism Section, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.

Ignacio Pérez de Castro (I)

Gene Therapy Unit, Instituto de Investigación de Enfermedades Raras, Instituto de Salud Carlos III (ISCIII), Madrid, Spain. iperez@isciii.es.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH